

Kazim Yalcin Arga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5284610/publications.pdf>

Version: 2024-02-01

92
papers

2,770
citations

218677

26
h-index

206112

48
g-index

101
all docs

101
docs citations

101
times ranked

3571
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-Mediated Drug Repurposing Unveiled Potential Candidate Drugs for Prolactinoma Treatment. <i>Neuroendocrinology</i> , 2022, 112, 161-173.	2.5	7
2	Decreased serum levels of glycerol-3- phosphate dehydrogenase 1 and monoacylglycerol lipase act as diagnostic biomarkers for breast cancer. <i>Cancer Biomarkers</i> , 2022, 34, 67-76.	1.7	3
3	Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks. <i>Archives of Biochemistry and Biophysics</i> , 2022, 715, 109085.	3.0	18
4	Past, Present, and Future of Therapies for Pituitary Neuroendocrine Tumors: Need for Omics and Drug Repositioning Guidance. <i>OMICS A Journal of Integrative Biology</i> , 2022, 26, 115-129.	2.0	2
5	Precision Diagnosis of Maturity-Onset Diabetes of the Young with Next-Generation Sequencing: Findings from the MODY-IST Study in Adult Patients. <i>OMICS A Journal of Integrative Biology</i> , 2022, 26, 218-235.	2.0	7
6	Multimiomics Data Integration Identifies New Molecular Signatures for Abdominal Aortic Aneurysm and Aortic Occlusive Disease: Implications for Early Diagnosis, Prognosis, and Therapeutic Targets. <i>OMICS A Journal of Integrative Biology</i> , 2022, 26, 290-304.	2.0	3
7	Driving Precision Oncology to Clinical Practice: The Road Ahead from Biomarker Validation to Clinical Decision Systems. <i>OMICS A Journal of Integrative Biology</i> , 2022, , .	2.0	1
8	Acute Myeloid Leukemia: New Multiomics Molecular Signatures and Implications for Systems Medicine Diagnostics and Therapeutics Innovation. <i>OMICS A Journal of Integrative Biology</i> , 2022, 26, 392-403.	2.0	5
9	Systems biology based drug repositioning for development of cancer therapy. <i>Seminars in Cancer Biology</i> , 2021, 68, 47-58.	9.6	54
10	Current State of Omics-Biomarkers in Pancreatic Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 127.	2.5	22
11	ETS-Domain Transcription Factor Elk-1 Regulates Stemness Genes in Brain Tumors and CD133+ BrainTumor-Initiating Cells. <i>Journal of Personalized Medicine</i> , 2021, 11, 125.	2.5	9
12	Differential Interactome Proposes Subtype-Specific Biomarkers and Potential Therapeutics in Renal Cell Carcinomas. <i>Journal of Personalized Medicine</i> , 2021, 11, 158.	2.5	8
13	The Repertoire of Glycan Alterations and Glycoproteins in Human Cancers. <i>OMICS A Journal of Integrative Biology</i> , 2021, 25, 139-168.	2.0	4
14	Recent Developments in Cancer Systems Biology: Lessons Learned and Future Directions. <i>Journal of Personalized Medicine</i> , 2021, 11, 271.	2.5	4
15	Unexpectedly lower mortality rates in COVID-19 patients with and without type 2 diabetes in Istanbul. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108753.	2.8	13
16	Cancer Stem Cell Transcriptome Profiling Reveals Seed Genes of Tumorigenesis: New Avenues for Cancer Precision Medicine. <i>OMICS A Journal of Integrative Biology</i> , 2021, 25, 372-388.	2.0	2
17	Monogenic Childhood Diabetes: Dissecting Clinical Heterogeneity by Next-Generation Sequencing in Maturity-Onset Diabetes of the Young. <i>OMICS A Journal of Integrative Biology</i> , 2021, 25, 431-449.	2.0	12
18	Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies. <i>EPMA Journal</i> , 2021, 12, 383-401.	6.1	8

#	ARTICLE	IF	CITATIONS
19	Thanatechnology and the Living Dead: New Concepts in Digital Transformation and Human-Computer Interaction. OMICS A Journal of Integrative Biology, 2021, 25, 401-407.	2.0	7
20	Systems-level biomarkers identification and drug repositioning in colorectal cancer. World Journal of Gastrointestinal Oncology, 2021, 13, 463-486.	2.0	0
21	Systems-level biomarkers identification and drug repositioning in colorectal cancer. World Journal of Gastrointestinal Oncology, 2021, 13, 638-661.	2.0	2
22	Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study. Diabetes Therapy, 2021, 12, 2857-2870.	2.5	11
23	Differential Protein Interactome in Esophageal Squamous Cell Carcinoma Offers Novel Systems Biomarker Candidates with High Diagnostic and Prognostic Performance. OMICS A Journal of Integrative Biology, 2021, 25, 495-512.	2.0	2
24	Differential Interactome Based Drug Repositioning Unraveled Abacavir, Exemestane, Nortriptyline Hydrochloride, and Tolcapone as Potential Therapeutics for Colorectal Cancers. Frontiers in Bioinformatics, 2021, 1, .	2.1	2
25	Artificial Intelligence as Accelerator for Genomic Medicine and Planetary Health. OMICS A Journal of Integrative Biology, 2021, 25, 745-749.	2.0	7
26	Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19. European Journal of Pharmacology, 2020, 887, 173594.	3.5	52
27	Comprehensive Analysis of RNA-Seq Gene Expression Profiling of Brain Transcriptomes Reveals Novel Genes, Regulators, and Pathways in Autism Spectrum Disorder. Brain Sciences, 2020, 10, 747.	2.3	45
28	Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 1273.	2.8	15
29	Transcriptomic profile of Pea3 family members reveal regulatory codes for axon outgrowth and neuronal connection specificity. Scientific Reports, 2020, 10, 18162.	3.3	6
30	<p>Omics-Driven Biomarkers of Psoriasis:ÂRecent Insights, Current Challenges, and Future Prospects</p>. Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 611-625.	1.8	17
31	Novel molecular signatures and potential therapeutics in renal cell carcinomas: Insights from a comparative analysis of subtypes. Genomics, 2020, 112, 3166-3178.	2.9	10
32	COVID-19 and the Futures of Machine Learning. OMICS A Journal of Integrative Biology, 2020, 24, 512-514.	2.0	11
33	Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib. Redox Biology, 2020, 32, 101502.	9.0	13
34	New Machine Learning Applications to Accelerate Personalized Medicine in Breast Cancer: Rise of the Support Vector Machines. OMICS A Journal of Integrative Biology, 2020, 24, 241-246.	2.0	44
35	Pathways involved in viral oncogenesis: New perspectives from virus-host protein interactomics. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165885.	3.8	15
36	Pan-cancer mapping of differential protein-protein interactions. Scientific Reports, 2020, 10, 3272.	3.3	36

#	ARTICLE	IF	CITATIONS
37	Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 148-159.	2.0	9
38	Cancer Drug Repositioning by Comparison of Gene Expression in Humans and Axolotl (<i>Ambystoma) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.0	6
39	Co-expression Network Analysis Elucidated a Core Module in Association With Prognosis of Non-functioning Non-invasive Human Pituitary Adenoma. <i>Frontiers in Endocrinology</i> , 2019, 10, 361.	3.5	23
40	Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis. <i>Medicina (Lithuania)</i> , 2019, 55, 20.	2.0	51
41	Multi-Omic Data Interpretation to Repurpose Subtype Specific Drug Candidates for Breast Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 420.	2.3	36
42	Identification of Novel Components of Target-of-Rapamycin Signaling Pathway by Network-Based Multi-Omics Integrative Analysis. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 274-284.	2.0	1
43	Novel Genomic Biomarker Candidates for Cervical Cancer As Identified by Differential Co-Expression Network Analysis. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 261-273.	2.0	32
44	Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning. <i>EBioMedicine</i> , 2019, 42, 386-396.	6.1	69
45	Drug Repositioning Strategies to Explore New Candidates Treating Prostate Cancer. , 2019, , 801-826.		2
46	Network-based approach to identify molecular signatures and therapeutic agents in Alzheimerâ€™s disease. <i>Computational Biology and Chemistry</i> , 2019, 78, 431-439.	2.3	92
47	A Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision Medicine. <i>Current Pharmaceutical Design</i> , 2019, 24, 3778-3790.	1.9	46
48	The Genome-Based Metabolic Systems Engineering to Boost Levan Production in a Halophilic Bacterial Model. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 198-209.	2.0	12
49	Systems biomarkers in psoriasis: Integrative evaluation of computational and experimental data at transcript and protein levels. <i>Gene</i> , 2018, 647, 157-163.	2.2	19
50	Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology Analyses. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 422-436.	2.0	49
51	Drug Repositioning for Effective Prostate Cancer Treatment. <i>Frontiers in Physiology</i> , 2018, 9, 500.	2.8	85
52	Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective. <i>PLoS ONE</i> , 2018, 13, e0200717.	2.5	89
53	Multimiomics Approach to Novel Therapeutic Targets for Cancer and Aging-Related Diseases: Role of Sld7 in Yeast Aging Network. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 100-113.	2.0	5
54	RNA-based ovarian cancer research from â€™a gene to systems biomedicineâ€™ perspective. <i>Systems Biology in Reproductive Medicine</i> , 2017, 63, 219-238.	2.1	18

#	ARTICLE	IF	CITATIONS
55	Ovarian Cancer Differential Interactome and Network Entropy Analysis Reveal New Candidate Biomarkers. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 285-294.	2.0	15
56	Transcriptomic analysis displays the effect of (-)-roemerine on the motility and nutrient uptake in <i>Escherichia coli</i> . <i>Current Genetics</i> , 2017, 63, 709-722.	1.7	9
57	Genome reprogramming in <i>Saccharomyces cerevisiae</i> upon nonylphenol exposure. <i>Physiological Genomics</i> , 2017, 49, 549-566.	2.3	9
58	Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: geneXpharma. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 584-591.	2.0	26
59	Multimiomics Analysis of Tumor Microenvironment Reveals Gata2 and miRNA-124-3p as Potential Novel Biomarkers in Ovarian Cancer. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 603-615.	2.0	42
60	Hypothesis: Are There Molecular Signatures of Yoga Practice in Peripheral Blood Mononuclear Cells?. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 426-428.	2.0	4
61	Differential co-expression analysis reveals a novel prognostic gene module in ovarian cancer. <i>Scientific Reports</i> , 2017, 7, 4996.	3.3	58
62	Analysis of transcriptional profiles of <i>Saccharomyces cerevisiae</i> exposed to bisphenol A. <i>Current Genetics</i> , 2017, 63, 253-274.	1.7	13
63	Cardiomyogenic differentiation potential of human lipoaspirate-derived stem cells on hyaluronic acid/gelatin plasma gels. <i>Turkish Journal of Biology</i> , 2016, 40, 369-379.	0.8	3
64	Omics of Selenium Biology: A Prospective Study of Plasma Proteome Network Before and After Selenized-Yeast Supplementation in Healthy Men. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 202-213.	2.0	24
65	Integration of multiple biological features yields high confidence human protein interactome. <i>Journal of Theoretical Biology</i> , 2016, 403, 85-96.	1.7	25
66	Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 645-661.	2.0	122
67	Molecular signatures of ovarian diseases: Insights from network medicine perspective. <i>Systems Biology in Reproductive Medicine</i> , 2016, 62, 266-282.	2.1	47
68	Interactive cooperation and hierarchical operation of microRNA and transcription factor crosstalk in human transcriptional regulatory network. <i>IET Systems Biology</i> , 2016, 10, 219-228.	1.5	23
69	Proteomic and Metabolic Signatures of Esophageal Squamous Cell Carcinoma. <i>Current Cancer Drug Targets</i> , 2016, 16, 721-736.	1.6	28
70	Proteomic and Metabolic Signatures of Esophageal Squamous Cell Carcinoma. <i>Current Cancer Drug Targets</i> , 2016, , .	1.6	11
71	Triple Negative Breast Cancer: A Multi-Omics Network Discovery Strategy for Candidate Targets and Driving Pathways. <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 115-130.	2.0	63
72	Genomic analysis of <i>Brevibacillus thermoruber</i> 423 reveals its biotechnological and industrial potential. <i>Applied Microbiology and Biotechnology</i> , 2015, 99, 2277-2289.	3.6	19

#	ARTICLE	IF	CITATIONS
73	Effective stimulating factors for microbial levan production by <i>Halomonas smyrnensis</i> AAD6T. <i>Journal of Bioscience and Bioengineering</i> , 2015, 119, 455-463.	2.2	81
74	Genomic analysis reveals the biotechnological and industrial potential of levan producing halophilic extremophile, <i>Halomonas smyrnensis</i> AAD6T. <i>SpringerPlus</i> , 2015, 4, 393.	1.2	32
75	Computational Systems Biology of Psoriasis: Are We Ready for the Age of Omics and Systems Biomarkers?. <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 669-687.	2.0	22
76	Tissue-Specific Molecular Biomarker Signatures of Type 2 Diabetes: An Integrative Analysis of Transcriptomics and Protein-Protein Interaction Data. <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 563-573.	2.0	70
77	Systems biology solutions to challenges in marine biotechnology. <i>Frontiers in Marine Science</i> , 2014, 1, .	2.5	4
78	GENETIC MUTATIONS ARE CHARACTERIZED BY INCREASE IN ENTROPY AT THE TRANSCRIPTIONAL LEVEL. <i>Journal of Biological Systems</i> , 2014, 22, 377-391.	1.4	2
79	The role of protein interaction networks in systems biomedicine. <i>Computational and Structural Biotechnology Journal</i> , 2014, 11, 22-27.	4.1	106
80	A system based network approach to ethanol tolerance in <i>Saccharomyces cerevisiae</i> . <i>BMC Systems Biology</i> , 2014, 8, 90.	3.0	19
81	The stimulatory effect of mannitol on levan biosynthesis: Lessons from metabolic systems analysis of <i>Halomonas smyrnensis</i> AAD6T. <i>Biotechnology Progress</i> , 2013, 29, 1386-1397.	2.6	38
82	Assessment of high-confidence protein-protein interactome in yeast. <i>Computational Biology and Chemistry</i> , 2013, 45, 1-8.	2.3	12
83	Draft Genome Sequence of Exopolysaccharide-Producing Thermophilic Bacterium <i>Brevibacillus thermoruber</i> Strain 423. <i>Genome Announcements</i> , 2013, 1, .	0.8	4
84	Draft Genome Sequence of <i>Halomonas smyrnensis</i> AAD6T. <i>Journal of Bacteriology</i> , 2012, 194, 5690-5691.	2.2	18
85	Genome-scale reconstruction of metabolic network for a halophilic extremophile, <i>Chromohalobacter salexigens</i> DSM 3043. <i>BMC Systems Biology</i> , 2011, 5, 12.	3.0	58
86	A cross-sectional study of biotechnology awareness and teaching in European high schools. <i>New Biotechnology</i> , 2010, 27, 822-828.	4.4	4
87	Drug targets for tumorigenesis: Insights from structural analysis of EGFR signaling network. <i>Journal of Biomedical Informatics</i> , 2009, 42, 228-236.	4.3	16
88	A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology. <i>Nature Biotechnology</i> , 2008, 26, 1155-1160.	17.5	530
89	Understanding signaling in yeast: Insights from network analysis. <i>Biotechnology and Bioengineering</i> , 2007, 97, 1246-1258.	3.3	28
90	Flux analysis of recombinant <i>Saccharomyces cerevisiae</i> YPB-G utilizing starch for optimal ethanol production. <i>Process Biochemistry</i> , 2004, 39, 2097-2108.	3.7	39

#	ARTICLE	IF	CITATIONS
91	Transfer function approach in structured modeling of recombinant yeast utilizing starch. Process Biochemistry, 2004, 39, 1237-1248.	3.7	4
92	Repositioning of Anti-Inflammatory Drugs for the Treatment of Cervical Cancer Sub-Types. Frontiers in Pharmacology, 0, 13, .	3.5	14